Research, Funding and Drug Development

Improvements in outcomes for cancer patients require continued research and innovation.  ACS CAN advocates for robust federal funding for cancer research, as well as research and drug approval policies that accelerate the development of new treatments while still ensuring patient safety.

Research, Funding and Drug Development Resources:

ACS CAN along with over 80 other patient organizations provided support and feedback to FDA regarding the creation of an Office of Patient Affairs that would help coordinate patient involvement at FDA.

Expanded access inovolves accessing unapproved therapies outside of clinical trials.  This process has been in existience since the late 1980s, and currently there have been calls to change the process.

The proposed DAIA legislation would modernize and harmonize diagnostic test oversight.  In this letter, ACS CAN shared with the legislation's sponsors specific feedback on ways to ensure the legislation meets the needs of cancer patients.  

Molecular tests are critical to safe, effective care for cancer patients, yet the oversight system for laboratory developed tests is in need of updating.  This letter, co-signed by 33 organizations, request that Congress act to ensure appropriate diagnostic oversight. 

ACS CAN supports the proposal to allow public databases to serve as a source of evidence to support regulatory demonstration of clinical validity of diagnostic tests.

This report examines the drug development landscape for childhood cancer, identifying scientific, logistical, economic and ethical challenges that are unique to pediatric cancer drug development. 

Letter providing support for the Prescription Drug User Fee Act (PDUFA) agreement negotiated between industry and FDA.  

This letter provides additional feedback on revised draft legislation for the oversight of laboratory developed tests (LDTs).  Specifically ACS CAN expressed concern for grandfathering provisions that would exempt many cancer diagnostics from appropriate regulatory oversight.

Immunology and immunotherapy have played an ever-increasing role in the understanding and treatment of cancer. Federal funding for research conducted by the National Institutes of Health(NIH) and the National Cancer Institute (NCI) play a key role in accelerating this progress.